Skip to main content
Premium Trial:

Request an Annual Quote

Miraculins Acquires Bankrupt Europroteome s IP Portfolio

NEW YORK, June 22 (GenomeWeb News) - Miraculins, a Winnipeg, Manitoba-based proteomics shop, has acquired the IP portfolio of Europroteome, a German molecular diagnostics company that filed for bankruptcy late last year, the company said.

According to Miraculins, the portfolio includes 14 patents and numerous discoveries related to the diagnosis of several cancers. The company said Miraculins has no further milestone or royalty commitments related to the patents. Miraculins said it plans to capitalize on the acquisition of the various biomarkers by developing assays to run on its mass spectrometry-based BEST platform. The company recently announced the completion of a prostate cancer diagnostic-discovery study.

Miraculins also announced that it has granted an aggregate of 25,000 stock options at an exercise price of $2.20 per common share to certain officers and directors in the company. The options are set to expire five years from date of grant and are subject to approval of the TSX Venture Exchange.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.